There were 2,410 press releases posted in the last 24 hours and 359,544 in the last 365 days.

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019

CRANBURY, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September.

  • Bradley Campbell, President and Chief Operating Officer, and Jeff Castelli, Chief Portfolio Officer and Head of Gene Therapy, will participate in a fireside chat at the Baird 2019 Global Healthcare Conference in New York, NY on Thursday, September 5, 2019 at 9:40 a.m. ET.
     
  • Daphne Quimi, Chief Financial Officer, will present at the Janney Healthcare Conference in New York, NY on Tuesday, September 10, 2019 at 11:50 a.m. ET.

A live audio webcast of both presentations can be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations, and will be archived for 90 days.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACTS:

Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Vice President, Investor Relations & Corporate Communications
IR@amicusrx.com
(609) 662-5044

Media:
Amicus Therapeutics
Marco Winkler
mwinkler@amicusrx.com
(609) 662-2798

FOLD–G

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.